StockData
Caris Life Sciences, Inc. logo

Caris Life Sciences, Inc. (CAI) stock

CAINasdaqServices-Medical LaboratoriesFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 4, 2026Score 7/3093% above fair value
$19.94−1.06 (-5.05%)

Close on Nov 17, 2026Market cap $5.63BP/E –Yield –

Caris Life Sciences profit margin

Profit margin (net margin) is net income as a percentage of revenue.

Caris Life Sciences's profit margin for the twelve months ending Sep 30, 2026 was 9.2%. For fiscal 2025 it was -8.4%, against -68.4% the year before.

Annual profit margin

PeriodPeriod endValueChange (pts)
FY2025Dec 31, 2025-8.4%+60.0
FY2024Dec 31, 2024-68.4%+43.2
FY2023Dec 31, 2023-111.5%–

Quarterly profit margin

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange (pts)
Q3 FY2026Sep 30, 20265.5%−5.7
Q2 FY2026Jun 30, 2026-0.2%+39.3
Q1 FY2026Mar 31, 2026-0.2%+84.6
Q4 FY2025Dec 31, 202528.0%+56.4
Q3 FY2025Sep 30, 202511.2%+77.9
Q2 FY2025Jun 30, 2025-39.6%+26.6
Q1 FY2025Mar 31, 2025-84.8%–
Q4 FY2024Dec 31, 2024-28.4%–
Q3 FY2024Sep 30, 2024-66.6%–
Q2 FY2024Jun 30, 2024-66.2%–

More Caris Life Sciences figures

See a number that looks wrong?